Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of BN-Brachyury Vaccine in Advanced Solid Tumors
NCT03349983Phase 1Completed
- Sponsor
- Bavarian Nordic
- Start
- Jan 2018
- Primary completion
- Jun 2020
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MVA-BN-Brachyury in solid tumor and chordoma, sponsored by Bavarian Nordic. Primary endpoint: Patients with Dose Limiting Toxicity up to 8 weeks. Started Jan 2018; status: completed.
02
Drugs
MVA-BN-Brachyury
03
Conditions
solid tumorchordoma
Beyond the preview
Go deeper on NCT03349983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03349983.